LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) Meeting Abstract
| Authors: | Azad, A.; Musto, C.; Netanel, S.; Zhang, T.; Rathkopf, D. E.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Runcie, K.; Dos Santos, A.; Bhaumik, A.; Mundle, S.; McCarthy, S.; Lopez-Gitlitz, A. M.; Batavia, A. S.; Sanchez, D. P.; Wildgust, M. A.; Agarwal, N. |
| Abstract Title: | LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406247 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS5119 |
| Notes: | Meeting Abstract: TPS5119 -- Source: Wos |
